DigestRedComo funciona
Red
/
Empresas
Re
No verificado

Recursion Pharmaceuticals, Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

4 Comunicados de prensa

Ver todos los comunicados de prensa
08/12/2025
Biotecnología
Medicina Salud Bienestar
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Fuente
Recursion Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0
Press Release cover image
20/11/2024
Biotecnología
Anuncios breves
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Fuente
Recursion Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0
22/10/2024
Biotecnología
Medicina Salud Bienestar
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Fuente
Recursion Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0
02/10/2024
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Fuente
Recursion Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0